Reliable Genotypic Tropism Tests for the Major HIV-1 Subtypes
Background: The major obstacles to the CCR5-antagonist maraviroc being more widely used in anti-HIV-1 therapy regimens are (i) traditional pre-treatment phenotypic tropism tests to determine virus susceptibility to maraviroc are expensive and time consuming, and (ii) cheaper and more rapid genotypic tropism tests have been developed primarily for HIV-1 subtype B strains, which account for…